<PAGE> 1
RULE 424(b)(3)
FILE NO. 33-38438
PROSPECTUS SUPPLEMENT DATED OCTOBER 11, 1996
TO SOMANETICS CORPORATION PROSPECTUS DATED APRIL 4, 1996
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
(x) Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended AUGUST 31, 1996
OR
( ) Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from to
--------------- -------------
Commission file number 0-19095
SOMANETICS CORPORATION
(Exact name of registrant as specified in its charter)
MICHIGAN 38-2394784
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1653 EAST MAPLE ROAD,
TROY, MICHIGAN
48083-4208
(Address of principal executive offices)
(Zip Code)
(810) 689-3050
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes X No
----------- ----------
Number of common shares outstanding at October 3, 1996: 19,185,101
<PAGE> 2
PART I FINANCIAL INFORMATION
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
<TABLE>
<CAPTION>
August 31, November 30,
1996 1995
ASSETS ------------ --------------
(Unaudited) (Audited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents........................................ $ 829,008 $ 941,426
Accounts receivable, net of allowance for doubtful accounts of $0
at August 31, 1996 and $194,000 at November 30, 1995........... 314,133 443,859
Inventory........................................................ 991,960 936,421
Prepaid expenses................................................. 43,352 72,161
----------- -----------
Total current assets........................................... 2,178,453 2,393,867
----------- -----------
PROPERTY AND EQUIPMENT (at cost):
Machinery and equipment.......................................... 452,158 412,217
Furniture and fixtures........................................... 192,749 193,339
Leasehold improvements........................................... 166,770 166,770
----------- -----------
Total.......................................................... 811,677 772,326
Less accumulated depreciation and amortization................... (726,810) (685,835)
----------- -----------
Net property and equipment..................................... 84,867 86,491
----------- -----------
OTHER ASSETS:
Note receivable - related party.................................. 202,125 190,240
Patents and trademarks, net...................................... 80,857 86,041
Other............................................................ 129,201 104,616
----------- -----------
Total other assets............................................. 412,183 380,897
----------- -----------
TOTAL ASSETS....................................................... $ 2,675,503 $ 2,861,255
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable................................................. $ 262,143 $ 131,401
Accrued liabilities.............................................. 32,263 416,356
----------- -----------
Total current liabilities........................................ 294,406 547,757
----------- -----------
COMMITMENTS AND CONTINGENCIES...................................... -- --
REDEEMABLE CONVERTIBLE PREFERRED SHARES............................ -- 19,843
SHAREHOLDERS' EQUITY:
Preferred shares, authorized, 1,000,000 shares of $.01 par value;
no shares issued or outstanding................................ -- --
Common shares, authorized, 30,000,000 shares of $.01 par
value; issued and outstanding, 19,154,118 and 17,768,552
shares at August 31, 1996 and November 30, 1995,
respectively................................................... 191,543 177,687
Additional paid-in capital....................................... 30,679,632 29,023,318
Deficit accumulated during the development stage................. (28,490,078) (26,907,350)
----------- -----------
Total shareholders' equity..................................... 2,381,097 2,293,655
----------- -----------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY......................... $ 2,675,503 $ 2,861,255
=========== ===========
</TABLE>
See notes to financial statements
2
<PAGE> 3
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF LOSS
(UNAUDITED)
<TABLE>
<CAPTION>
Cumulative
for the Period
January 15, 1982
Three Months Nine Months (Date of Inception)
Ended August 31, Ended August 31, To
--------------------------- ---------------------------- August 31,
1996 1995 1996 1995 1996
----------- ----------- ----------- ----------- ------------------
<S> <C> <C> <C> <C> <C>
REVENUES:
Net Sales............................. $ 99,541 $ 171,652 $ 699,006 $ 1,078,277 $ 5,649,738
Research and development activities... -- -- -- -- 122,500
----------- ----------- ----------- ----------- ------------
Total revenues....................... 99,541 171,652 699,006 1,078,277 5,772,238
COST OF SALES.......................... 67,700 93,192 327,151 524,208 2,569,266
----------- ----------- ----------- ----------- ------------
GROSS MARGIN........................... 31,841 78,460 371,855 554,069 3,202,972
----------- ----------- ----------- ----------- ------------
OPERATING EXPENSES:
Research, development, and
engineering........................ 44,685 50,232 147,353 240,796 7,916,910
Selling, general and administrative... 678,766 923,150 1,878,482 2,774,069 24,518,265
----------- ----------- ----------- ----------- ------------
Total operating expenses............. 723,451 973,382 2,025,835 3,014,865 32,435,175
----------- ----------- ----------- ----------- ------------
OPERATING LOSS......................... (691,610) (894,922) (1,653,980) (2,460,796) (29,232,203)
----------- ----------- ----------- ----------- ------------
OTHER INCOME (EXPENSE):
Interest income....................... 19,569 20,425 51,980 71,867 1,111,525
Interest expense...................... -- -- -- (772) (231,225)
Other................................. 8,099 1,066 19,272 1,991 (118,333)
----------- ----------- ----------- ----------- ------------
Total other income................... 27,668 21,491 71,252 73,086 761,967
----------- ----------- ----------- ----------- ------------
NET LOSS............................... $ (663,942) $ (873,431) $(1,582,728) $(2,387,710) $(28,470,236)
=========== =========== =========== =========== ============
NET LOSS PER COMMON SHARE.............. $ (.03) $ (.05) $ (.09) $ (.14) $ (4.07)
----------- ----------- ----------- ----------- ------------
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING.............. 19,109,288 17,067,465 18,365,476 16,536,516 6,986,968
=========== =========== =========== =========== ============
</TABLE>
See notes to financial statements
3
<PAGE> 4
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIENCY)
(UNAUDITED)
(1 OF 2)
<TABLE>
<CAPTION>
PRICE
PER SHARE
DATE SHARE SHARES VALUE
---- ----- ------ -----
<S> <C> <C> <C> <C>
ISSUANCE OF COMMON SHARES:
For shareholders' contributions of test equipment ......... January, 1982 $ 0.032 830,376 $ 8,304
For cash .................................................. July, 1982 1.31 78,345 783
Net loss from January 15, 1982 (date of inception)
to November 30, 1982 ...................................
--------- -------
Balance at November 30, 1982 ................................ 908,721 9,087
For cash .................................................. December, 1982 1.31 39,172 392
For services .............................................. January, 1983 1.31 15,669 157
For cash, less issuance costs of $5,863 ................... July, 1983 2.62 116,243 1,162
For services .............................................. November, 1983 2.62 7,834 78
Net loss for the year ended November 30, 1983 .............
--------- -------
Balance at November 30, 1983 ................................ 1,087,639 10,876
For cash, less issuance costs December, 1983-
of $7,735 .............................................. April, 1984 2.62 194,212 1,943
For patents ............................................... February, 1984 2.62 48,944 489
For cash .................................................. November, 1984 3.51 37,303 373
Net loss for the year ended November 30, 1984 .............
--------- -------
Balance at November 30, 1984 ................................ 1,368,098 13,681
For cash, less issuance costs December, 1984-
of $3,726 .............................................. June, 1985 3.51 130,292 1,303
For cash .................................................. November, 1985 7.02 144,838 1,448
Net loss for the year ended November 30, 1985 .............
--------- -------
Balance at November 30, 1985 ................................ 1,643,228 16,432
Exercise of stock options for cash ........................ December, 1985 3.51 7,834 79
For cash .................................................. January, 1986 7.02 104,442 1,044
Net loss for the year ended November 30, 1986 .............
--------- -------
Balance at November 30, 1986 ................................ 1,755,504 17,555
For cash, less issuance costs March, 1987-
of $9,500 .............................................. September, 1987 5.11 103,591 1,036
Net loss for the year ended November 30, 1987 .............
--------- -------
Balance at November 30, 1987 ................................ 1,859,095 18,591
For cash, less issuance costs February, 1988-
of $10,500 ............................................. April, 1988 5.11 32,905 329
Net loss for the year ended November 30, 1988 .............
--------- -------
Balance at November 30, 1988 ................................ 1,892,000 18,920
For cash and the exchange of debt January, 1989-
due a shareholder ...................................... July, 1989 5.11 45,244 452
Net loss for the year ended November 30, 1989 .............
--------- -------
Balance at November 30, 1989 ................................ 1,937,244 19,372
For services .............................................. August, 1990 5.11 47,006 471
Net loss for the year ended November 30, 1990 .............
--------- -------
Balance at November 30, 1990 ................................ 1,984,250 19,843
For cash, less issuance costs of $1,630,241 ............... March, 1991 2.00 3,600,000 36,000
Unit Purchase Option ...................................... March, 1991
Redeemable Convertible Preferred Stock dividend ........... April, 1991
For cash, less issuance costs of $126,900 ................. April, 1991 2.00 540,000 5,400
Net loss for the year ended November 30, 1991 .............
--------- -------
Balance at November 30, 1991 ................................ 6,124,250 $61,243
<CAPTION>
TOTAL
ADDITIONAL ACCUM- SHAREHOLDERS'
PAID-IN ULATED EQUITY
CAPITAL DEFICIT (DEFICIENCY)
---------- ------- ------------
<S> <C> <C> <C>
ISSUANCE OF COMMON SHARES:
For shareholders' contributions of test equipment ......... $ 18,196 $ - $ 26,500
For cash .................................................. 101,217 102,000
Net loss from January 15, 1982 (date of inception)
to November 30, 1982 ................................... (107,083) (107,083)
----------- ------------ -------------
Balance at November 30, 1982 ................................ 119,413 (107,083) 21,417
For cash .................................................. 50,608 51,000
For services .............................................. 20,343 20,500
For cash, less issuance costs of $5,863 ................... 297,139 298,301
For services .............................................. 20,422 20,500
Net loss for the year ended November 30, 1983 ............. (291,986) (291,986)
----------- ------------ -------------
Balance at November 30, 1983 ................................ 507,925 (399,069) 119,732
For cash, less issuance costs
of $7,735 .............................................. 498,503 500,446
For patents ............................................... 127,580 128,069
For cash .................................................. 130,563 130,936
Net loss for the year ended November 30, 1984 ............. (700,380) (700,380)
----------- ------------ -------------
Balance at November 30, 1984 ................................ 1,264,571 (1,099,449) 178,803
For cash, less issuance costs
of $3,726 .............................................. 452,312 453,615
For cash .................................................. 1,015,352 1,016,800
Net loss for the year ended November 30, 1985 ............. (559,871) (559,871)
----------- ------------ -------------
Balance at November 30, 1985 ................................ 2,732,235 (1,659,320) 1,089,347
Exercise of stock options for cash ........................ 27,421 27,500
For cash .................................................. 732,157 733,201
Net loss for the year ended November 30, 1986 ............. (1,222,772) (1,222,772)
----------- ------------ -------------
Balance at November 30, 1986 ................................ 3,491,813 (2,882,092) 627,276
For cash, less issuance costs
of $9,500 .............................................. 518,364 519,400
Net loss for the year ended November 30, 1987 ............. (1,143,081) (1,143,081)
----------- ------------ -------------
Balance at November 30, 1987 ................................ 4,010,177 (4,025,173) 3,595
For cash, less issuance costs
of $10,500 ............................................. 157,171 157,500
Net loss for the year ended November 30, 1988 ............. (352,311) (352,311)
----------- ------------ -------------
Balance at November 30, 1988 ................................ 4,167,348 (4,377,484) (191,216)
For cash and the exchange of debt
due a shareholder ...................................... 230,548 231,000
Net loss for the year ended November 30, 1989 ............. (446,642) (446,642)
----------- ------------ -------------
Balance at November 30, 1989 ................................ 4,397,896 (4,824,126) (406,858)
For services .............................................. 239,529 240,000
Net loss for the year ended November 30, 1990 ............. (1,328,518) (1,328,518)
----------- ------------ -------------
Balance at November 30, 1990 ................................ 4,637,425 (6,152,644) (1,495,376)
For cash, less issuance costs of $1,630,241 ............... 5,533,759 5,569,759
Unit Purchase Option ...................................... 120 120
Redeemable Convertible Preferred Stock dividend ........... (19,843) (19,843)
For cash, less issuance costs of $126,900 ................. 947,700 953,100
Net loss for the year ended November 30, 1991 ............. (2,058,493) (2,058,493)
----------- ------------ -------------
Balance at November 30, 1991 ................................ $11,119,004 $(8,230,980) $ 2,949,267
</TABLE>
4
<PAGE> 5
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIENCY)
(UNAUDITED)
(2 OF 2)
<TABLE>
<CAPTION>
PRICE
PER SHARE
DATE SHARE SHARES VALUE
---- ----- ------ -----
<S> <C> <C> <C> <C>
Balance at November 30, 1991................................. 6,124,250 $ 61,243
Exercise of Class A Warrants for cash, December, 1991-
less issuance costs of $702,917 ........................ May, 1992 3.00 4,139,000 41,390
February, 1992-
Exercise of Class B Warrants for cash ..................... November, 1992 4.00 34,055 341
July, 1992- 2.00-
Exercise of stock options for cash ........................ November, 1992 2.19 30,100 301
Net loss for year ended November 30, 1992 .................
---------- --------
Balance at November 30, 1992 ................................ 10,327,405 103,275
December, 1992-
Exercise of Class B Warrants for cash ..................... October, 1993 4.00 29,766 298
March, 1993-
Exercise of Class M Warrants for cash ..................... October, 1993 1.00 600,179 6,002
March, 1993- 2.00-
Exercise of Stock Options for cash ........................ September, 1993 4.38 3,100 31
Exercise of Unit Purchase
Options and Underlying Class A Warrants May, 1993- 3.00-
for cash ............................................... October, 1993 3.30 10,002 100
Net loss for the year ended November 30, 1993 .............
---------- --------
Balance at November 30, 1993 ................................ 10,970,452 109,706
For cash, less issuance costs of $490,790 ................. August, 1994 0.80 5,297,000 52,970
Exercise of Stock Options for Cash......................... November, 1994 1.63-
3.59 100 1
Net loss for the year ended November 30, 1994 .............
---------- --------
Balance at November 30, 1994 ................................ 16,267,552 162,677
Exercise of Stock Options for Cash ........................ February, 1995 0.84 1,000 10
For cash, less issuance costs of $282,475 ................. July, 1995 1.25 1,500,000 15,000
Net loss for the year ended November 30, 1995 .............
---------- --------
Balance at November 30, 1995 ................................ 17,768,552 177,687
Exercise of Stock Options for Cash ........................ January, 1996 0.84 20,000 200
February, 1996 0.84- 46,666 467
1.00
For cash, less issuance costs of $143,587 ................. April, 1996 1.25 1,142,400 11,424
Exercise of Stock Options for Cash ........................ May, 1996 1.33 7,800 78
Exercise of Stock Options for Cash ........................ June, 1996 .84- 2,700 27
1.47
Exercise of Warrants for Cash ............................. June, 1996- 1.75- 166,000 1,660
July, 1996 2.00
Net loss for the nine month period ended
August 31, 1996 .........................................
---------- --------
Balance at August 31, 1996 .................................. 19,154,118 $191,543
========== ========
<CAPTION>
TOTAL
ADDITIONAL ACCUM- SHAREHOLDERS'
PAID-IN ULATED EQUITY
CAPITAL DEFICIT (DEFICIENCY)
---------- ------- ------------
<S> <C> <C> <C>
Balance at November 30, 1991................................. $11,119,004 $ (8,230,980) $ 2,949,267
Exercise of Class A Warrants for cash,
less issuance costs of $702,917 ........................ 11,672,693 11,714,083
Exercise of Class B Warrants for cash ..................... 135,879 136,220
Exercise of stock options for cash ........................ 65,774 66,075
Net loss for year ended November 30, 1992 ................. (5,390,637) (5,390,637)
----------- ------------- -----------
Balance at November 30, 1992 ................................ 22,993,350 (13,621,617) 9,475,008
Exercise of Class B Warrants for cash ..................... 118,766 119,064
Exercise of Class M Warrants for cash ..................... 594,177 600,179
Exercise of Stock Options for cash ........................ 13,119 13,150
Exercise of Unit Purchase
Options and Underlying Class A Warrants
for cash ............................................... 31,406 31,506
Net loss for the year ended November 30, 1993 ............. (6,135,830) (6,135,830)
----------- ------------- -----------
Balance at November 30, 1993 ................................ 23,750,818 (19,757,447) 4,103,077
For cash, less issuance costs of $490,790 ................. 3,693,840 3,746,810
Exercise of Stock Options for Cash.........................
201 202
Net loss for the year ended November 30, 1994 ............. (4,331,500) (4,331,500)
----------- ------------- -----------
Balance at November 30, 1994 ................................ 27,444,859 (24,088,947) 3,518,589
Exercise of Stock Options for Cash ........................ 834 844
For cash, less issuance costs of $282,475 ................. 1,577,625 1,592,625
Net loss for the year ended November 30, 1995 ............. (2,818,403) (2,818,403)
----------- ------------- -----------
Balance at November 30, 1995 ................................ 29,023,318 (26,907,350) 2,293,655
Exercise of Stock Options for Cash ........................ 16,675 16,875
44,116 44,583
For cash, less issuance costs of $143,587 ................. 1,272,989 1,284,413
Exercise of Stock Options for Cash ........................ 10,261 10,339
Exercise of Stock Options for Cash ........................ 3,283 3,310
Exercise of Warrants for Cash ............................. 308,990 310,650
Net loss for the nine month period ended
August 31, 1996 ......................................... (1,582,728) (1,582,728)
----------- ------------- -----------
Balance at August 31, 1996 .................................. $30,679,632 $(28,490,078) $ 2,381,097
=========== ============= ===========
</TABLE>
See notes to financial statements
5
<PAGE> 6
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Cumulative
for the Period
January 15, 1982
Nine Months (Date of Inception)
Ended August 31, to
-------------------------------- August 31,
1996 1995 1996
----------- ----------- ------------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss............................................................... $(1,582,728) $(2,387,710) $(28,470,236)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization........................................ 47,530 113,028 810,517
Expenses paid through the issuance of common shares.................. -- -- 408,068
Loss on disposal of property......................................... -- -- 44,861
Changes in assets and liabilities:
Accounts receivable (increase) decrease............................ 129,726 72,552 (314,133)
Inventory (increase)............................................... (55,539) (43,556) (991,960)
Prepaid expenses (increase) decrease............................... 28,809 19,713 (43,352)
Other assets (increase)............................................ (24,585) (16,793) (239,933)
Accounts payable increase.......................................... 130,742 10,926 262,143
Accrued liabilities increase (decrease)............................ (384,093) 27,707 32,263
----------- ----------- ------------
Net cash (used in) operations..................................... (1,710,138) (2,204,132) (28,501,762)
----------- ----------- ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of marketable securities..................................... -- -- (12,166,540)
Proceeds from sale of marketable securities............................ -- 1,564,826 12,166,540
Acquisition of property and equipment (net)............................ (40,722) (18,157) (882,869)
Disbursement or accrual for note receivable - related party............ (11,885) (11,083) (202,125)
----------- ----------- ------------
Net cash (used in) provided by investing activities............... (52,607) 1,535,586 (1,084,994)
----------- ----------- ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Common Shares................................ 1,670,170 1,589,564 30,435,607
Redemption of Convertible Preferred Shares............................. (19,843) -- (19,843)
Proceeds from issuance of notes payable and long-term debt............. -- -- 2,515,223
Repayments of notes payable and long-term debt......................... -- (30,000) (2,515,223)
----------- ----------- ------------
Net cash provided by financing activities......................... 1,650,327 1,559,564 30,415,764
----------- ----------- ------------
NET INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS............................................................ (112,418) 891,017 829,008
CASH AND CASH EQUIVALENTS, BEGINNING
OF PERIOD.............................................................. 941,426 840,245 --
----------- ----------- ------------
CASH AND CASH EQUIVALENTS, END
OF PERIOD.............................................................. $ 829,008 $ 1,731,262 $ 829,008
=========== =========== ============
</TABLE>
SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING ACTIVITIES:
See Statements of Shareholders' Equity (Deficiency) for details of shares
issued in exchange for noncash consideration.
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest for the nine-month periods ended August 31, 1996 and
1995 approximated $0 and $800, respectively.
See notes to financial statements.
6
<PAGE> 7
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
1. ORGANIZATION AND OPERATIONS
Somanetics Corporation (the "Company") is a Michigan corporation formed in
January 1982 to develop, manufacture and market processor-based medical
diagnostic and patient monitoring equipment. The equipment utilizes the
Company's "In Vivo Optical Spectroscopy," or "INVOS(R)" technology to provide
analyses of human blood and tissue. The Company is in the development stage
and has incurred research, product development and other expenses involved in
designing, developing, marketing and selling its products, as well as devoting
efforts to raising capital.
The Company is using its INVOS technology in processor-based medical equipment
(the INVOS Cerebral Oximeter and related single-patient use SomaSensor(R)) that
non-invasively and continuously monitors trends in regional hemoglobin oxygen
saturation of blood in the brain of an individual.
2. FINANCIAL STATEMENT PRESENTATION
The accompanying unaudited interim financial statements of Somanetics
Corporation have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission. Accordingly, such financial statements do
not include all of the information and footnotes normally included in the
Company's annual financial statements prepared in accordance with generally
accepted accounting principles, although the Company believes that the
disclosures are adequate to make the information presented not misleading.
The accompanying unaudited interim financial statements reflect all
adjustments which are, in the opinion of management, necessary to a fair
statement of the results for the interim periods presented. All such
adjustments are of a normal recurring nature, except those described in Note
5 and those not material to the Company's financial condition. Operating
results for the nine-month period ended August 31, 1996, are not necessarily
indicative of the results that may be expected for the year ending
November 30, 1996, although the Company expects to continue to incur operating
losses for the foreseeable future. These financial statements should be read
in conjunction with the financial statements and footnotes thereto for the
year ended November 30, 1995 included in the Company's Annual Report on Form
10-K for the fiscal year ended November 30, 1995.
The Company is in the development stage and, accordingly, has not achieved
sales necessary to support operations. The Company has incurred an accumulated
deficit of $28,490,078 through August 31, 1996. The Company had working
capital of $1,884,047, cash and cash equivalents of $829,008, total current
liabilities of $294,406 and shareholders' equity of $2,381,097, as of August
31, 1996.
7
<PAGE> 8
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
Although on June 6, 1996 the Company received clearance from the FDA to market
the Cerebral Oximeter in the United States, the Company's current financial
condition and recent results of operations and the status of its product
marketing efforts and sales have been affected by the process of obtaining such
clearance. On November 22, 1993, the Company received notification that the
FDA had rescinded the Company's 510(k) clearance to market the Cerebral
Oximeter. As a result, all commercial sales of the Company's products were
suspended and the Company notified its United States distributors to stop
selling the Cerebral Oximeter and to advise their customers to stop using the
device. In February 1994, the Company resumed marketing its products in
several foreign countries, including Japan, its largest market outside the
United States.
On February 1, 1995, the Company filed a new 510(k) application with the FDA.
On October 5, 1995, the Company received a written response from the FDA,
stating that the FDA could not determine if the device was substantially
equivalent to a legally marketed device, and that the FDA considered the
Company's 510(k) submission to be withdrawn. On February 13, 1996, the Company
filed a new 510(k) application with the FDA presenting additional information
not previously considered by the agency, identifying alternative predicate
devices and offering revisions to its product and its labeling. On June 6,
1996, the Company received clearance to market the INVOS 3100A Cerebral
Oximeter in the United States.
The Company currently is marketing Cerebral Oximeters and SomaSensors in 25
foreign countries, with sales in 13 countries in the first nine months of
1996. The Company expects to begin marketing the Cerebral Oximeter in other
countries after complying with each country's local laws. The Company began
marketing the Cerebral Oximeter in the United States on a limited basis in the
third quarter; most of the third quarter was devoted to product introduction
activities and replacing existing Cerebral Oximeters with the INVOS 3100A
Cerebral Oximeter. Product introduction activities, including engaging United
States distributors and hiring direct sales personnel, are expected to
continue into the fourth quarter. There can be no assurance that sales will
continue or increase as a result of such marketing efforts, or that, even if
they increase, they will provide sufficient cash to fund the Company's
operations or make the Company profitable.
As of August 31, 1996 the Company had 21 employees and four consultants. The
Company expects to hire 16 additional employees before the end of the fiscal
year, 12 in Sales and Marketing (three of whom have been hired), 1 in Research
and development (who has been hired), 2 in Manufacturing and Quality Control
(both of whom have been hired) and 1 in Administration. The Company expects to
incur these expenses before receiving substantially increased proceeds from
sales of its products, and such expenses will continue even if revenues do not
increase. Therefore, in the short-run, they are expected to increase the
Company's net losses.
8
<PAGE> 9
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
Management believes that markets exist for the products the Company has
developed; however, there is an inherent uncertainty associated with the
success of such new products. The likelihood of success of the Company must be
considered in view of the Company's limited resources and current financial
condition, the problems and expenses frequently encountered in connection with
formation of a new business, the ability to raise new funds, the development
and application of new technology, and the competitive environment in which the
Company intends to operate.
The net proceeds from previous sales of securities were sufficient to fund the
Company's working capital requirements into the third quarter ended August 31,
1996. Current sales are not sufficient to fund operations. On April 2, 1996,
the Company completed the placement of 571,200 Units, at a price of $2.50 per
Unit, for gross proceeds of $1,428,000, through an offering complying with
Regulation S under the Securities Act of 1933, as amended. The net proceeds to
the Company, after deducting the placement agents' fee and the expenses of the
offering, were approximately $1,284,000. Each Unit consists of two
newly-issued Common Shares, par value $0.01 per share, and one warrant to
purchase one Common Share.
The Warrants are immediately exercisable and transferable separately from the
Common Shares. Each Warrant entitles the holder to purchase one Common Share at
an initial exercise price of $1.75 per share, subject to adjustment, at any
time through April 1, 2001, unless earlier redeemed. The Warrants are
redeemable for $0.01 by the Company at any time if certain conditions are met.
The Company also granted the placement agent warrants to purchase 114,240
Common Shares at $1.25 per share exercisable during the four-year period
beginning April 2, 1997.
Pursuant to an amended agreement with Rauscher Pierce & Clark, Inc. and
Rauscher Pierce & Clark Limited (collectively, the "Placement Agent") in
connection with the Regulation S offering, the Company has agreed to permit a
person designated by the Placement Agent to attend meetings of the Company's
Board of Directors until the 1998 Annual Meeting of Shareholders and to
participate in discussions at such meetings. The Placement Agent has not yet
designated such person. The Company is no longer required by its agreements
with the Placement Agent to expand the size of its Board of Directors by two
persons or to appoint persons nominated or acceptable to the Placement Agent to
fill the vacancies.
Also during the third quarter, the Company received net proceeds of $313,961
from the exercise of various outstanding warrants and stock options.
Effective February 28, 1996, the Company redeemed all of its outstanding
Convertible Preferred Shares for $.01 per share at a total redemption cost to
the Company of approximately $19,843, and instead of the Convertible Preferred
Shares formerly issuable
9
<PAGE> 10
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
upon the exercise of certain options, the Company will pay $.01 to the person
exercising such options for each Convertible Preferred Share otherwise
receivable.
The Company believes that the cash and cash equivalents on hand at August 31,
1996 will be sufficient to sustain the Company's operations at budgeted levels
and its needs for liquidity into the fourth quarter of fiscal 1996. By that
time the Company will be required to raise additional cash either through
additional sales of products, through sales of securities, by incurring
additional indebtedness or by some combination of the foregoing. If the
Company is unable to raise additional cash by that time, it will be required to
further reduce or discontinue its operations.
The expected uses of the Company's cash and cash equivalents are based on
certain estimates and assumptions made by the Company. Such estimates and
assumptions are subject to change as a result of actual experience. There can
be no assurance that actual capital requirements necessary to market the
Cerebral Oximeter and SomaSensor, to develop enhancements to, and product
extensions of, the Cerebral Oximeter, to conduct research and development
concerning additional potential applications of INVOS technology and for
working capital will not be substantially greater than current estimates.
The Company does not believe that product sales will be sufficient to fund the
Company's operations in the fourth quarter ending November 30, 1996.
In September 1996, the Company received approximately, $29,400 from the
exercise of the remaining 30,983 outstanding Class M Warrants.
The Company proposes to offer up to 1,500,000 Common Shares, par value $.01 a
share, in an offering complying with Regulation S under the Securities Act of
1933, as amended (the "Act"). The Common Shares offered will not be registered
under the Act and may not be offered or sold in the United States or to a U.S.
person absent registration or an applicable exemption from the registration
requirements. However, such sales are subject to negotiation of definitive
agreements and the identification of sufficient interested buyers. There can
be no assurance that the Company will be able to raise additional cash.
As of August 31, 1996, there were 4,075,179 redeemable Class B Warrants and
5,001 non-redeemable Class B Warrants outstanding, all exercisable at $3.89 per
share, subject to adjustment. On September 13, 1996, the Company announced the
extension of the redemption date for its redeemable Class B Warrants, and the
expiration date for its non-redeemable Class B Warrants, to November 14, 1996.
Any Class B Warrants which have not been exercised before November 14, 1996
will no longer be exercisable to purchase Common Shares. Holders of Class B
Warrants will have no further rights beyond November 14, 1996, except to
receive, upon surrender of the Class B Warrant certificates evidencing redeemed
10
<PAGE> 11
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
Class B Warrants, payment of the redemption price of $.05 for each redeemable
Class B Warrant outstanding and not already exercised as of November 14, 1996.
There can be no assurance that additional Class B Warrant holders will
exercise their Warrants and it is unlikely they will do so as long as the
exercise price exceeds the market price of the Common Shares. The Company has
the right to reduce the exercise price of the Class B Warrants, to extend the
redemption date or both. If the proposed offering of Common Shares (described
above) is successful and if the Company determines not to further extend the
redemption date of its Class B Warrants, the Company expects to use a portion
of the proceeds of that offering to redeem its outstanding Class B Warrants.
Also as of August 31, 1996, there were 604,000 redeemable warrants outstanding,
exercisable at $2.00 a share until July 13, 2000, and 551,200 redeemable
warrants outstanding exercisable at $1.75 a share until April 1, 2001. These
warrants were issued in the Company's 1995 and 1996 Regulation S securities
offerings. The conditions permitting the Company to redeem these warrants have
not been met as of October 1, 1996. Between June 1, 1996 and July 12, 1996,
146,000 of the warrants exercisable at $2.00 a share and 20,000 of the warrants
exercisable at $1.75 a share had been exercised. There can be no assurance
that additional warrants will be exercised and it is unlikely that they will be
exercised if the exercise price exceeds the market price of the Common Shares.
The Company has the right to reduce the exercise price of these warrants.
Effective March 19, 1996, all outstanding Unit Purchase Options expired. None
of the Unit Purchase Options had been exercised between December 1, 1995 and
March 19, 1996.
The Company has no commitments for additional loans.
These factors, among others, raise substantial doubt about the Company's
ability to continue as a going concern. The financial statements do not
include any adjustments relating to the recoverability and classification of
asset carrying amounts or the amount and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Inventory is stated at the lower of cost or market on a first-in, first-out
(FIFO) basis. Inventory consists of:
<TABLE>
<CAPTION>
August 31, 1996 November 30, 1995
--------------- -----------------
<S> <C> <C>
Finished goods $455,343 $516,420
Work in process 305,412 219,076
Purchased components 231,205 200,925
-------- --------
Total $991,960* $936,421
======== ========
</TABLE>
* Net of an approximately $153,000 reserve for obsolete and excess inventory.
11
<PAGE> 12
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
Patents and Trademarks are recorded at cost and are being amortized on the
straight-line method over 17 years. Accumulated amortization was $30,876 and
$25,692 at August 31, 1996 and November 30, 1995, respectively.
Loss Per Common Share is computed using the weighted average number of Common
Shares outstanding during each period. Common Shares issuable under stock
options and warrants have not been considered in the computation of the net
loss per Common Share because such inclusion would be antidilutive.
4. ACCRUED LIABILITIES
Accrued liabilities consist of the following:
<TABLE>
<CAPTION>
August 31, 1996 November 30, 1995
--------------- -----------------
<S> <C> <C>
Professional fees $ 17,391 $ 75,702
Warranty 13,651 15,000
Insurance 3,122
Product Upgrades 32,848 149,954
Shareholder Lawsuits (Note 5) (34,719) 144,717
Other - 30,983
-------- --------
Total $ 32,263 $416,356
======== ========
</TABLE>
For a description of the change in the reserve for product upgrades, see Note
5.
5. COMMITMENTS AND CONTINGENCIES
Before the Company received FDA clearance to market the Cerebral Oximeter in
the United States, several domestic distributors of the INVOS Cerebral Oximeter
expressed their desire to terminate their distributor agreements with the
Company. The Company does not believe that their distributor agreements
require it to accept returns of products sold to distributors in connection
with a termination of the distribution agreement. The Company, however,
reserved $194,000 at November 30, 1995, for the uncollectibility of accounts
receivable from such distributors.
The Company terminated 11 of its 15 domestic distributors in fiscal 1996.
12
<PAGE> 13
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
Because of the significant change in the composition of the Company's U.S.
distributors, the change in the product being marketed by the U.S.
distributors (the INVOS 3100A, rather than the INVOS 3100), and the changed
terms and conditions applicable to the new and continuing distributors, the
Company wrote off substantially all of its receivables from domestic
distributors in exchange for the return of their, and their customers', old
INVOS 3100 Cerebral Oximeters and SomaSensors.
Additionally, in the third quarter ended August 31, 1996, the Company reversed
its reserves for the extra cost of exchanging new INVOS 3100A Cerebral Oximeters
with such persons for their old devices, for the costs of upgrading the old
devices for resale and for the cost of replacing SomaSensors recalled in 1993.
Additional distributors might terminate their agreements with the Company or be
terminated by the Company. Distributor terminations may increase the Company's
costs. There can be no assurance that the Company will be able to replace
distributors desiring to terminate their distribution agreements, engage
distributors or direct sales employees in additional territories, or retain its
existing distributors. The Company's inability to retain distributors or
engage replacement distributors or direct sales employees could have a material
adverse effect on its ability to market and sell its product.
Purchasers of eight units (out of a total of eighteen units) of the INVOS 2100
System, a product previously marketed by the Company have requested refunds
claiming, in some cases, that the device identified too many women as having a
high risk of breast cancer. The Company believes that the devices are
functioning as intended and that the purchasers have no contractual or other
right to return the devices and are not entitled to refunds. No provision has
been recorded in the financial statements for any refunds that may become due
to such purchasers or for any product liability claims because the Company
believes that successful assertion of the claims does not appear probable and
the ultimate amount of the loss, if any,
13
<PAGE> 14
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
cannot be reasonably estimated. If the Company must refund all or a
significant portion of the sales price for the INVOS 2100, or is exposed to any
product liability claims, its financial condition and liquidity could be
adversely affected.
The Company has not received any correspondence or inquiries regarding the
INVOS 2100 since fiscal 1991, except for a letter dated August 3, 1994, from
the FDA warning manufacturers of breast transillumination devices that these
devices are in violation of the Federal Food Drug and Cosmetics Act ("the Act")
in that their labeling is false or misleading and fails to bear adequate
directions for use. The Company responded to the FDA by explaining the INVOS
2100 had not been available for sale by the Company commercially or otherwise
since January 1989. The Company has not received any correspondence or
inquiries regarding the INVOS 2100 since fiscal 1991 (other than the August 3,
1994 letter from the FDA) and believes the devices currently in the domestic
marketplace are no longer being used, based on the manner in which the unit is
to be used and the instructions in the user manual. The Company believes no
further action is required.
On March 14, 1994, a shareholder of the Company filed suit in the United States
District Court for the Eastern District of Michigan, individually and on behalf
of all others similarly situated, against the Company, four of its present and
former directors and four other officers, former officers or employees of the
Company in an action captioned Jacobson, et al v. Somanetics Corporation, et
al. The plaintiff alleged that various registration statements filed under the
Securities Act of 1933, various reports filed under the Securities Exchange Act
of 1934 and various annual reports and press releases contained material
misstatements and omissions and that the Company and the named officers, former
officers and employees of the Company made material misstatements and
omissions. The plaintiffs sought recovery pursuant to Sections 11, 12(2) and
15 of the Securities Act of 1933, Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, Rule 10b-5 under the Securities Exchange Act of 1934 and
under common law for (i) rescission of their investment and compensation for
the lost use of the money invested, (ii) other compensatory damages, (iii)
punitive damages in the amount of $10,000,000, (iv) consequential damages, (v)
reasonable attorneys' fees, (vi) costs and disbursements and (vii) such other
relief as the court may deem just and proper.
On April 25, 1994, another shareholder of the Company filed suit in the United
States District Court for the Eastern District of Michigan, individually and on
behalf of all others similarly situated, against the Company and Gary D. Lewis,
the Company's former Chairman of the Board, in an action captioned Benjamin
Langford v. Somanetics Corporation and Gary D. Lewis. The allegations, relief
requested and consequences of the action are similar to those in the Jacobson
case described above.
The Company entered into a Stipulation And Agreement Of Compromise And
Understanding (the "Agreement") with counsel for plaintiff Earl J. Jacobson.
On July 3, 1996 the court
14
<PAGE> 15
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
issued a final judgment approving the Agreement and certifying the class.
The Agreement (along with an understanding with the Company's insurance
company) requires the Company to pay $250,000 in cash, less the amount of its
legal fees incurred in this action, and the Company's insurance company is
required to pay $250,000 in cash, plus the amount the Company has incurred in
attorneys' fees. Pursuant to the Agreement, the Company and its insurance
company paid an aggregate of $500,000 to an escrow agent in the second quarter
ended May 31, 1996. However, approximately 11 persons, including Benjamin
Langford, have opted out of the Jacobson action and this settlement and,
therefore, are not barred by the settlement from pursuing their own claims
against the Company. Mr. Langford's action is still pending against the
Company, although it is no longer a class action. The Company's motion to
dismiss the Langford action was denied and discovery is proceeding.
The ultimate outcome of the Langford litigation cannot presently be determined.
If the Company must pay any additional significant amount to defend or settle
the Langford lawsuit or if it must pay a significant judgment in connection
with this lawsuit, its financial condition and liquidity could be materially
adversely affected, and capital intended for use in the marketing of the
Cerebral Oximeter or to develop enhancements to, or product extensions of, the
Cerebral Oximeter or other products may have to be reallocated to satisfy any
such requirements. In addition, any such expenses will, when incurred, have
the effect of increasing the Company's net loss (or decreasing its net income)
during the periods in which they are incurred.
The Company may become subject to product liability claims by patients or
doctors and may become a defendant in product liability or malpractice
litigation. The Company has obtained product liability insurance and an
umbrella policy. There can be no assurance that the Company will be able to
retain such insurance or that such insurance would be sufficient to protect the
Company against such product liability.
6. SUBSEQUENT EVENTS
In September 1996, the Company entered into a Master Distribution
Agreement with MedLink Europe, an operational services company located in
Amsterdam, with offices in other parts of Europe. MedLink helps U.S.-based
companies execute their marketing activities throughout Europe, and is expected
to provide the Company with sales and marketing support as well as
distribution, customer service and technical and product service.
The Company has entered into a Consulting Order with NeuroPhysics Corporation,
of Groton, Massachusetts, a research and development company, pursuant to which
the Company is supporting NeuroPhysics' research into the feasibility and
development of prototypes of four new products. In exchange, NeuroPhysics has
granted the Company certain rights in the new products, subject to the rights
of the United States Federal government, which is also funding
15
<PAGE> 16
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
AUGUST 31, 1996
the research, in the new products and a royalty in favor of NeuroPhysics.
The potential new products are noninvasive, in vivo, near-infrared
spectroscopy devices that monitor liver oxygenation for assessing and
controlling hemorrahagic shock, locate and assess subdural hematomas in
head trauma patients, monitor certain blood gases and monitor fetal cerebral
blood oxygenation during labor and delivery. There can be no assurance that
the Company will be able to successfully apply the INVOS technology or related
technologies in the development of commercially viable products or that
competitors will not develop and market similar products before the Company
does.
16
<PAGE> 17
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
LIQUIDITY AND CAPITAL RESOURCES
Somanetics Corporation is a development stage company formed to develop,
manufacture and market processor-based medical diagnostic and patient
monitoring equipment using INVOS(R) technology. Since inception (January 15,
1982), the Company has incurred an accumulated deficit of $28,490,078 through
August 31, 1996.
Net cash used in operations during the nine-month period ended August 31, 1996
was approximately $1,710,000. Cash was used primarily to (i) fund the
Company's net loss, consisting primarily of selling, general and administrative
expenses and research, development and engineering expenses (approximately
$1,535,000, net of depreciation and amortization expense), (ii) decrease
accrued liabilities (approximately $384,000) primarily as a result of the (a)
payment of professional fees, (b) payment of expenses and settlement costs
associated with the class action lawsuits, (c) reversal of its reserve to
exchange unpaid domestic INVOS 3100 Cerebral Oximeters for new INVOS 3100A's
and upgrade the INVOS 3100's received, (d) reversal of its reserve to replace
the 1993 recalled domestic SomaSensors, and (e) exchange of paid INVOS 3100's
for new INVOS 3100A's, and (iii) increase inventory (approximately $56,000) as
a result of increased manufacturing activity in preparation for domestic sales
and returns of INVOS 3100's before shipment of replacement INVOS 3100A's.
These uses of cash were partially offset by (i) a decrease in accounts
receivable (approximately $130,000) due to reduced sales, and (ii) a $131,000
increase in accounts payable due to increased legal and professional expenses,
slower payment of trade payables and increased inventory purchases. Management
expects working capital requirements to increase if sales increase.
Effective February 28, 1996, the Company redeemed all of its outstanding
Convertible Preferred Shares for $.01 per share at a total redemption cost to
the Company of approximately $19,843, and instead of the Convertible Preferred
Shares formerly issuable upon the exercise of certain options, the Company will
pay $.01 to the person exercising such options for each Convertible Preferred
Share otherwise receivable.
On April 2, 1996, the Company completed the placement of 571,200 Units, at a
price of $2.50 per Unit, for gross proceeds of $1,428,000, through an offering
complying with Regulation S under the Securities Act of 1933, as amended. The
net proceeds to the Company, after deducting the placement agents' fee and the
expenses of the offering, were approximately $1,284,000. Each Unit consists of
two newly-issued Common Shares, par value $0.01 per share, and one warrant to
purchase one Common Share.
The Warrants are immediately exercisable and transferable separately from the
Common Shares. Each Warrant entitles the holder to purchase one Common Share at
an initial exercise
17
<PAGE> 18
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
price of $1.75 per share, subject to adjustment, at any time through April 1,
2001, unless earlier redeemed. The Warrants are redeemable for $0.01 by the
Company at any time after July 2, 1996, if certain conditions are met.
The Company also granted the placement agent warrants to purchase 114,240
Common Shares at $1.25 per share exercisable during the four-year period
beginning April 2, 1997.
Between June 1, 1996 and July 12, 1996, 146,000 warrants issued in the
Company's 1995 Regulation S offering and exercisable at $2.00 a share, and
20,000 warrants issued in the Company's 1996 Regulation S offering and
exercisable at $1.75 a share, were exercised, and the Company paid the
placement agent in such offerings a $16,350 fee in connection with those
exercises. Also, during the first three quarters of fiscal 1996, the Company
has received approximately $75,000 from the exercise of employee stock options.
As of August 31, 1996, the Company had working capital of $1,884,047 and cash
and cash equivalents of $829,008.
The Company believes that the cash and cash equivalents on hand at August 31,
1996 will be sufficient to sustain the Company's operations at budgeted levels
and its needs for liquidity into the fourth quarter of fiscal 1996. By that
time the Company will be required to raise additional cash either through
additional sales of products, through sales of securities, by incurring
additional indebtedness or by some combination of the foregoing. If the
Company is unable to raise additional cash by that time, it will be required to
reduce or discontinue its operations.
The expected uses of the Company's cash and cash equivalents are based on
certain estimates and assumptions made by the Company. Such estimates and
assumptions are subject to change as a result of actual experience, and there
can be no assurance that actual capital requirements necessary to market the
Cerebral Oximeter and SomaSensor, to develop enhancements to, and product
extensions of, the Cerebral Oximeter, to conduct research and development
concerning additional potential applications of INVOS and other technology and
for working capital will not be substantially greater than current estimates.
Although on June 6, 1996 the Company received clearance from the FDA to market
the Cerebral Oximeter in the United States, the Company's current financial
condition and recent results of operations and the status of its product
marketing efforts and sales have been affected by the process of obtaining such
clearance. On November 22, 1993, the Company received notification that the
FDA had rescinded the Company's 510(k) clearance to market the Cerebral
Oximeter. As a result, all commercial sales of the Company's products were
suspended and the Company notified its United States distributors to stop
selling the Cerebral Oximeter and to advise their customers to stop using the
device. In February 1994, the Company resumed
18
<PAGE> 19
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
marketing its products in several foreign countries, including Japan, its
largest market outside the United States.
On February 1, 1995, the Company filed a new 510(k) application with the FDA.
On October 5, 1995, the Company received a written response from the FDA,
stating that the FDA could not determine if the device was substantially
equivalent to a legally marketed device, and that the FDA considered the
Company's 510(k) submission to be withdrawn. On February 13, 1996, the Company
filed the new 510(k) application with the FDA presenting additional information
not previously considered by the agency, identifying alternative predicate
devices and offering revisions to its product and its labeling. On June 6,
1996, the Company received clearance to market the INVOS Cerebral Oximeter in
the United States.
The Company does not believe that product sales will be sufficient to fund the
Company's operations in the fourth quarter ending November 30, 1996.
In September 1996, the Company received approximately $29,400 from the exercise
of the remaining 30,983 outstanding Class M Warrants.
The Company proposes to offer up to 1,500,000 Common Shares, par value $.01 a
share, in an offering complying with Regulation S under the Securities Act of
1933, as amended (the "Act"). The Common Shares offered will not be registered
under the Act and may not be offered or sold in the United States or to a U.S.
person absent registration or an applicable exemption from the registration
requirements. However, such sales are subject to negotiation of definitive
agreements and the identification of sufficient interested buyers. There can
be no assurance that the Company will be able to raise additional cash.
The Company did not receive any proceeds from the exercise of Class B Warrants
during the nine-month period ended August 31, 1996. As of March 31, 1992, the
Company gave notice of the redemption of the redeemable Class B Warrants at
$.05 per Class B Warrant. The Company has extended the redemption date ten
times, most recently to November 14, 1996. Any redeemable Class B Warrants
which have not been exercised before November 14, 1996, will no longer be
exercisable to purchase Common Shares. Holders of redeemable Class B Warrants
will have no further rights beyond November 14, 1996, except to receive, upon
surrender of the Class B Warrant certificates evidencing redeemed Class B
Warrants, payment of the redemption price of $.05 for each redeemable Class B
Warrant outstanding and not already exercised as of November 14, 1996. As of
October 1, 1996, the closing sale price of the Common Shares was $2.063. As of
August 31, 1996, 4,080,180 Class B Warrants were outstanding, including 5,001
non-redeemable Class B Warrants, each exercisable to purchase one Common Share
at $3.89 a share, subject to adjustment. There can be no assurance that
additional Class B Warrant holders will exercise their Warrants and it is
unlikely that they will do so as long as the exercise price exceeds the market
price of the Common Shares. The
19
<PAGE> 20
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
Company has the right to reduce the exercise price of the Class B Warrants,
extend the redemption date, or both. If the proposed offering of Common Shares
(described above) is successful and if the Company determines not to further
extend the redemption date of its Class B Warrants, the Company expects to use
a portion of the proceeds of that offering to redeem its outstanding Class B
Warrants. The maximum potential redemption price for the Class B Warrants is
$203,759, which the Company will be required to pay in November 1996 if the
Class B Warrants are redeemed.
Also as of August 31, 1996, there were 604,000 redeemable warrants outstanding,
exercisable at $2.00 a share until July 13, 2000, and 551,200 redeemable
warrants outstanding exercisable at $1.75 a share until April 1, 2001. These
warrants were issued in the Company's 1995 and 1996 Regulation S securities
offerings. The conditions permitting the Company to redeem these warrants have
not been met as of October 1, 1996. There can be no assurance that additional
warrants will be exercised and it is unlikely that they will be exercised if
the exercise price exceeds the market price of the Common Shares. The Company
has the right to reduce the exercise price of these warrants.
Effective March 19, 1996, all outstanding Unit Purchase Options expired. None
of the Unit Purchase Options had been exercised between December 1, 1995 and
March 19, 1996.
The Company has no loan commitments.
There can be no assurance that even if the Company receives additional capital,
it will be able to achieve the level of sales necessary to sustain its
operations. There can be no assurance that the Company will be able to obtain
any funds on terms acceptable to the Company and at times required by the
Company through sales of the Company's products, sales of securities or loans
in sufficient quantities.
Before the Company received FDA clearance to market the Cerebral Oximeter in
the United States, several domestic distributors of the INVOS Cerebral Oximeter
expressed their desire to terminate their distributor agreements with the
Company. The Company does not believe that their distributor agreements
require it to accept returns of products sold to distributors in connection
with a termination of the distribution agreement. The Company, however, has
reserved $194,000 at November 30, 1995, for the uncollectibility of accounts
receivable from such distributors.
The Company terminated 11 of its 15 domestic distributors in fiscal 1996, and
plans to have 6 United States distributors for its products and additional
employees selling its product directly in the remaining territories. The
Company has entered into new distribution agreements with three of its four
existing United States distributors on different terms and conditions,
including different prices. It expects to add the remaining three
20
<PAGE> 21
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
distributors and additional direct sales personnel in fiscal 1996. There can
be no assurance that the Company will be able to replace its terminated
United States distributors, and any inability to retain distributors or
engage replacement distributors could have a material adverse effect on its
ability to market and sell its product. Because of the significant change in
the composition of the Company's U.S. distributors, the change in the product
being marketed by the U.S. distributors (the INVOS 3100A, rather than the INVOS
3100), and the changed terms and conditions applicable to the new and
continuing distributors, the Company wrote off substantially all of its
receivables from domestic distributors in exchange for the return of their, and
their customers', old INVOS 3100 Cerebral Oximeters and SomaSensors (which
returns resulted in a $68,000 recovery of bad debts in the third quarter ended
August 31, 1996). Because the Company has more INVOS 3100 Cerebral Oximeters
that it expects to sell in the next year, the Company accrued a reserve for the
value of the devices in excess of one year's supply in the third quarter ended
August 31, 1996 (approximately $47,300).
The Company intends to upgrade the returned INVOS 3100 Cerebral Oximeters and
sell them in countries that do not require compliance with the standards met by
the INVOS 3100A Cerebral Oximeter. In addition, the Company intends to sell
(rather than exchange) INVOS 3100A Cerebral Oximeters to United States
distributors and customers who had not paid for the INVOS 3100 Cerebral
Oximeters they returned to the Company. Therefore, in the third quarter ended
August 31, 1996, the Company reversed its $57,200 reserve for the extra cost of
exchanging new INVOS 3100A Cerebral Oximeters with such persons for their old
devices and for the costs of upgrading the old devices for resale. Continuing
distributors and customers who paid for their INVOS 3100 Cerebral Oximeters
will be permitted to exchange their old devices for a new one. As a result,
each distributor and customer will only pay once and will receive a new model
Cerebral Oximeter. The Company also reversed its $27,000 reserve for the cost
of replacing SomaSensors recalled in 1993.
On March 14, 1994, a shareholder of the Company filed suit in the United States
District Court for the Eastern District of Michigan, individually and on behalf
of all others similarly situated, against the Company, four of its present and
former directors and four other officers, former officers or employees of the
Company in an action captioned Jacobson, et al v. Somanetics Corporation, et
al. The plaintiff alleges that various registration statements filed under the
Securities Act of 1933, various reports filed under the Securities Exchange Act
of 1934 and various annual reports and press releases contained material
misstatements and omissions and that the Company and the named officers, former
officers and employees of the Company made material misstatements and
omissions. The plaintiffs seek recovery pursuant to Sections 11, 12(2) and 15
of the Securities Act of 1933, Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, Rule 10b-5 under the Securities Exchange Act of 1934 and
under common law for (i) rescission of their investment and compensation for
the lost use of the money invested, (ii) other compensatory damages, (iii)
punitive damages in the amount of
21
<PAGE> 22
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
$10,000,000, (iv) consequential damages, (v) reasonable attorney's fees, (vi)
costs and disbursements and (vii) such other relief as the court may deem just
and proper.
On April 25, 1994, another shareholder of the Company filed suit in the United
States District Court for the Eastern District of Michigan, individually and on
behalf of all others similarly situated, against the Company and Gary D. Lewis,
the Company's former Chairman of the Board, in an action captioned Benjamin
Langford v. Somanetics Corporation and Gary D. Lewis. The allegations, relief
requested and consequences of the action are similar to those in the Jacobson
case described above.
The Company entered into a Stipulation And Agreement Of Compromise And
Understanding (the "Agreement") with counsel for plaintiff Earl J. Jacobson.
On July 3, 1996 the court issued a final judgement approving the Agreement and
certifying the class. The Agreement (along with an understanding with the
Company's insurance company) requires the Company to pay $250,000 in cash, less
the amount of its legal fees incurred in this action, and the Company's
insurance company is required to pay $250,000 in cash, plus the amount the
Company has incurred in attorneys' fees. Pursuant to the Agreement, the
Company and its insurance company paid an aggregate of $500,000 to an escrow
agent in the second quarter ended May 31, 1996. However, approximately 11
persons, including Benjamin Langford, have opted out of the Jacobson action and
this settlement and, therefore, are not barred by the settlement from pursuing
their own claims against the Company. Mr. Langford's action is still pending
against the Company although it is no longer a class action. The Company's
motion to dismiss the action was denied and discovery is proceeding.
The ultimate outcome of the Langford litigation cannot presently be determined.
If the Company must pay any significant additional amount to defend or settle
the Langford lawsuit or if it must pay a significant judgment in connection
with this lawsuit, its financial condition and liquidity could be materially
adversely affected, and capital intended for use in the marketing of the
Cerebral Oximeter or to develop enhancements to, or product extensions of, the
Cerebral Oximeter or other products may have to be reallocated to satisfy any
such requirements. In addition, any such expenses will, when incurred, have
the effect of increasing the Company's net loss (or decreasing its net income)
during the periods in which they are incurred.
RESULTS OF OPERATIONS
Since the Company's inception (January 15, 1982) its primary activities have
consisted of research and development of the INVOS technology, the INVOS 2100,
the INVOS Cerebral Oximeter and the related disposable SomaSensor. The Company
is in the development stage and has accumulated losses of $28,470,236.
22
<PAGE> 23
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
For the three and nine-month periods ended August 31, 1996, the Company
realized a 24% and a 34% reduction in the respective net losses over the same
periods in fiscal 1995. The decrease for the nine-month period is primarily
attributable to a 33% reduction in operating expenses, partially offset by a
35% reduction in sales.
During the three-month periods ended August 31, 1996 and 1995, the Company
recognized revenues of $99,541 and $171,652, respectively. For the nine-month
periods ended August 31, 1996 and 1995, the Company recognized revenues of
$699,006 and $1,078,277, respectively. The decrease in sales for the third
quarter of 1996, as compared to the third quarter of 1995, is primarily
attributable to a more than 20% decrease in the average selling price of
Cerebral Oximeters to distributors and lower sales in the European market.
The decrease in sales for the nine-month period was primarily attributable to
a more than 20% decrease in the average selling price of Cerebral Oximeters to
distributors and reduced shipments to Europe and to Baxter Limited in Japan.
Sales of refurbished units, commercial units and SomaSensors comprised
approximately 43%, 26% and 31%, respectively, of the Company's sales in the
third quarter of fiscal 1996 and 19%, 45%, and 36%, respectively, of the
Company's sales in the third quarter of fiscal 1995. Sales of refurbished
units, commercial units and SomaSensors comprised approximately 12%, 70% and
18%, respectively, of the Company's sales in the nine months ended August 31,
1996, and 9%, 74% and 17%, respectively, of the Company's sales in the nine
months ended August 31, 1995. All 1995 and approximately 70% (for the third
quarter) and approximately 95% (for the first nine months) of 1996 sales were
export sales. Two international distributors accounted for approximately 68%
and 14%, respectively, of total revenues for the nine months ended August 31,
1996 and three international distributors accounted for approximately 49%, 25%
and 9%, respectively, of total revenues for the three months ended August 31,
1996. Two international distributors accounted for approximately 53% and 12%,
respectively, of total revenues in the nine months ended August 31, 1995, and
two international distributors accounted for approximately 30% and 26%,
respectively, of total revenues in the three months ended August 31, 1995.
As described above in "Liquidity and Capital Resources," all commercial sales
were suspended in late November 1993, upon notification from the FDA that it
was rescinding the Company's 510(k) clearance. FDA clearance is necessary to
allow the Company to market its product in the United States. On June 6, 1996,
the Company received clearance from the United States Food and Drug
Administration to market its INVOS 3100A Cerebral Oximeter in the United
States. See "Liquidity and Capital Resources" for a description of the effects
of the FDA's rescission of the Company's 510(k) clearance in 1993 on the
Company's distributors and terminations of distributors.
23
<PAGE> 24
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
There can be no assurance that the publication of adverse results from research
regarding the Cerebral Oximeter, the events leading to a voluntary recall of
SomaSensors in October 1993, the FDA's rescission of the Company's 510(k)
clearance for the Cerebral Oximeter in 1993, the FDA's actions relating to the
INVOS 2100 and the Company's financial condition will not adversely affect the
Company's reputation or its ability to market and sell its device.
The Company expects Cerebral Oximeter sales to increase from third quarter 1996
levels, although Baxter Limited is not expected to order again until the first
or second quarter of fiscal 1997 and the Company expects to continue to engage
its remaining United States distributors and hire direct sales personnel in the
fourth quarter of fiscal 1996. The Company expects sales of the disposable
SomaSensor to become a larger portion of the Company's revenues in the future
after the Company sells a significant number of Cerebral Oximeters to
distributors and they are resold to hospitals. No assurance can be given that
sales of the Cerebral Oximeter and SomaSensor will provide sufficient cash to
fund the Company's operations, and the Company does not believe that product
sales will be sufficient to fund the Company's operations in the fourth quarter
ending November 30, 1996.
Gross margin as a percentage of revenues for the quarters ended August 31, 1996
and 1995 were approximately 32% and 46%, respectively. Gross margin as a
percentage of revenues for the nine-month periods ended August 31, 1996 and
1995 were approximately 53% and 51%, respectively. Gross margin as a
percentage of revenues decreased for the quarter ended August 31, 1996 from the
fiscal 1995 level, primarily because 43% of total revenues in the three-month
period ended August 31, 1996 consisted of sales of refurbished Cerebral
Oximeters, which are sold approximately at cost, thereby reducing overall gross
margin and an increase in the cost of the SomaSensor, partially offset by an
approximately 10% decrease in materials cost for the Cerebral Oximeter. Gross
margin as a percentage of revenues increased in the nine-month period ended
August 31, 1996 over the same period in 1995 primarily because the materials
cost for the oximeter has decreased approximately 10%, partially offset by an
increase in the cost of the SomaSensor and increased sales of refurbished
Cerebral Oximeters. Excluding sales of refurbished units, gross margins
increased slightly over the same period in 1995 primarily as a result of lower
material costs for the oximeter, partially offset by lower average selling
prices for the Cerebral Oximeter.
The direct and indirect costs to manufacture Cerebral Oximeters are expected to
decline as a percentage of sales as and if (i) the Company increases sales,
production and volume purchases, and (ii) the Company ceases to incur
non-recurring tooling and manufacturing charges. However, the Company expects
to incur additional non-recurring tooling costs, manufacturing costs and
engineering costs in fiscal 1996 in connection with enhancements to the
SomaSensor and the production of the INVOS 3100A Cerebral Oximeter. Any new
products or enhancements developed during fiscal 1996 might also increase such
costs. In
24
<PAGE> 25
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
addition, margins might be favorably impacted if direct sales by the
Company in the United States increase the Company's average selling price of
its products.
The Company incurred research, development and engineering expenses of $44,685
and $50,232 for the fiscal quarters ended August 31, 1996 and 1995,
respectively, and $147,353 and $240,796 for the nine-month periods ended August
31, 1996 and 1995, respectively. The decrease for the nine-month period is
primarily attributable to an approximately $70,000 charge (in 1995) to
engineering expenses for obsolete purchased parts inventory relating to
engineering design changes to the Cerebral Oximeter model designed to comply
with TUV. The decrease for the three-month period is primarily attributable to
one fewer engineer. Research, development and engineering activities in fiscal
1996 consisted primarily of defending the previous 510(k) applications,
preparing and filing a new 510(k) application in February 1996, developing
improvements to the SomaSensor and completing modifications to the INVOS
Cerebral Oximeter requested by the FDA. Such activities in fiscal 1995
consisted primarily of developing improvements to the SomaSensor, evaluating
the results of the clinical trials supporting the 510(k) submission (for the
nine-month period), preparing and defending the 510(k) application and gaining
the CE mark and CSA certification for the INVOS 3100A Cerebral Oximeter (for
the nine-month period) and purchasing materials.
Research, development and engineering expenses are expected to increase due to
(i) the hiring of three additional persons in this department since May 31,
1996 to support new projects, and (ii) projects for new product development,
testing and possible future marketing. The Company expects to incur research,
development and engineering expense to develop and test product extensions of
the Cerebral Oximeter for use on newborns in operating rooms and intensive care
units, enhancements to the Cerebral Oximeter and other uses of the Company's
technology and related technologies. The Company has entered into a Consulting
Order with NeuroPhysics Corporation pursuant to which the Company is supporting
NeuroPhysics' research into the feasibility and development of prototypes of
four new products. See Note 6 of Notes to Financial Statements. The Company
expects this order to increase its research and development expenses by
approximately $11,000 a month.
Selling, general and administrative expenses for the fiscal quarters ended
August 31, 1996 and 1995 totaled $678,766 and $923,150, respectively, and
$1,878,482 and $2,774,069 for the nine-month periods ended August 31, 1996 and
1995, respectively. For the three-month period ended August 31, 1996 over the
same period in 1995, the decrease is primarily due to a $101,000 reduction in
salaries, wages and related expenses, a $75,000 reduction in other fees, a
$45,000 reduction in facility expenses, a $68,000 bad debt recovery, a
$57,000 reversal of the Cerebral Oximeter exchange and upgrade reserve, and a
$27,000 reversal of the reserve for replacing SomaSensors recalled in 1993,
partially offset by a $47,000 reserve accrued for excess INVOS 3100 Cerebral
Oximeters in inventory and a $40,000 increase in selling-related expenses. The
decrease for the nine-month period ended August 31, 1996 from the same
25
<PAGE> 26
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
period in 1995 is primarily due to a $499,000 reduction in salaries, wages and
related expenses, a $107,000 reduction in selling-related expenses, a $132,000
reduction in facility expenses, a $104,000 reduction in other fees, a $68,000
bad debt recovery, a $57,000 reversal of the Cerebral Oximeter exchange and
upgrade reserve, and a $27,000 reversal of the reserve for replacing
SomaSensors recalled in 1993, partially offset by a $47,000 reserve accrued for
excess INVOS 3100 Cerebral Oximeters in inventory.
Salaries, wages, and related expenses, including expenses for temporary
employees and consulting services, decreased approximately $101,000, or 21%,
for the fiscal quarter ended August 31, 1996 over the fiscal quarter ended
August 31, 1995, and approximately $499,000, or 34%, for the nine-month period
ended August 31, 1996 over the same period in 1995. The decreases for the
three- and nine-month periods over the comparable periods in 1995 are primarily
attributable to reductions in payroll and related benefits as a result of a
reduction in workforce from an average of 25 employees during the periods ended
August 31, 1995 to an average of 18-19 employees during the periods ended
August 31, 1996, and for the nine-month period, reductions in the incentive
compensation accrual and consulting services. The Company has hired 11
employees (and four consultants) since May 31, 1996 and expects to hire 10
additional employees as needed, 9 in Sales and Marketing and 1 in
Administration during the remainder of fiscal 1996 which will increase
salaries, wages and related expenses in the future. The Company expects to
incur these expenses before receiving substantially increased proceeds from
sales of its products, and such expenses will continue even if revenues do not
increase. Therefore, in the short-run, they are expected to increase the
Company's net losses.
Selling expenses, including expenses for travel, entertainment, marketing,
clinical research and industry trade show participation, increased
approximately $40,000, or 41%, for the fiscal quarter ended August 31, 1996
over the fiscal quarter ended August 31, 1995, and decreased approximately
$107,000, or 37%, for the nine-month period ended August 31, 1996 over the same
period in 1995. The increase for the three-month period ended August 31, 1996
over the same period in 1995 is primarily attributable to additional
distributor support and demonstration units placed in the domestic market
place, partially offset by a reduction in clinical research and travel-related
expenses associated with training the Company's international distributors.
The decrease for the nine-month period was primarily due to reduced clinical
research and travel-expenses associated with training the Company's
international distributors and reduced expenses associated with trade show
participation. The Company expects selling, marketing, travel, entertainment
and trade show expenses to increase in conjunction with resumed marketing in
the United States, engaging and training new United States distributors and
additional direct sales personnel and supporting existing distributors and
increased sales efforts in the international markets. Clinical research
expenses are expected to increase as the Company tests product extensions of
the Cerebral Oximeter in a clinical setting.
26
<PAGE> 27
SOMANETICS CORPORATION
(A DEVELOPMENT STAGE COMPANY)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
AUGUST 31, 1996
Monthly office expenses, including lease commitments, supplies, subscriptions
and related expenses decreased approximately $45,000, or 34%, for the
three-month period ended August 31, 1996, over the same period last year, and
approximately $132,000, or 33%, for the nine- month period ended August 31,
1996 over the same period in 1995, primarily due to the reduction in personnel
and the expiration of operating lease commitments. The Company expects these
expenses to increase as the Company hires additional personnel.
As described in "Liquidity and Capital Resources", in the third quarter ended
August 31, 1996, (i) returns of INVOS 3100 Cerebral Oximeters by domestic
distributors whose receivables had been written off resulted in a $68,000
recovery of bad debts, (ii) the Company accrued a $47,300 reserve for the value
of INVOS 3100 Cerebral Oximeters in excess of one year's supply, (iii) the
Company reversed its $57,200 reserve for the extra cost of exchanging new INVOS
3100A Cerebral Oximeters for INVOS 3100 Cerebral Oximeters held by domestic
distributors who had not yet paid for their devices, and the cost of upgrading
the old devices for a new one, and (iv) the Company reversed its $27,000
reserve for the replacement of SomaSensors recalled in 1993. These amounts are
included in Selling, General and Administrative expenses for the third quarter
ended August 31, 1996.
Other income, including interest income and expense, increased approximately
$6,000 for the three-month period ended August 31, 1996 over the comparable
three-month period in fiscal 1995, and decreased approximately $2,000 for the
nine-month period ended August 31, 1996 over the comparable nine-month period
in fiscal 1995. The increase in the three-month period ended August 31, 1996
over the same period last year, is the result of sub-lease income received on a
portion of the Company's facilities, partially offset by a reduction in
interest income primarily as a result of the lower balance of cash available
for investment. For the nine-month period ended August 31, 1996, the reduction
is the result of reduced interest income, partially offset by sub-lease income
from a portion of the Company's facilities. The Company expects interest
income to decrease as it continues to use cash in its operations, unless its
proposed offering of Common Shares is successful, thereby increasing its cash
available for investment purposes.
Each of the above statements regarding future revenues or expenses may be a
"forward looking statement" within the meaning of the Securities Exchange Act
of 1934. Such statements are subject to important factors that could cause
actual results to differ materially from those in the forward-looking
statement, including the factors set forth in this Management's Discussion and
Analysis of Financial Condition and Results of Operations, and the factors set
forth under the caption "Risk Factors" on pages 15-25 of the prospectus
included in Post-Effective Amendment No. 6 to the Company's Registration
Statement on Form S-1 (file no. 33-38438; effective April 4, 1996).
27
<PAGE> 28
PART II OTHER INFORMATION
Item 1. Legal Proceedings
For a description of the settlement effective July 3, 1996 of a suit filed by a
shareholder of the Company on March 14, 1994 in the United States District
Court for the Eastern District of Michigan, individually and on behalf of all
others similarly situated, against the Company, four current and former
directors and four other officers, former officers or employees of the Company
in an action captioned Jacobson, et al v. Somanetics Corporation, et al, see
Note 5 of Notes to Financial Statements included in Part I of this Report,
which description is incorporated in this Item 1 by reference.
For a description of a suit filed by another shareholder of the Company on
April 25, 1994 in the United States District Court for the Eastern District of
Michigan, individually and on behalf of all others similarly situated, against
the Company and Gary D. Lewis, the Company's former Chairman, in an action
captioned Benjamin Langford v. Somanetics Corporation and Gary D. Lewis, see
Note 5 of Notes to Financial Statements included in Part I of this Report,
which description is incorporated in this Item 1 by reference.
As described in Note 5, on July 3, 1996, the court issued a final judgement
approving the Stipulation And Agreement of Compromise And Understanding,
regarding the settlement of the Jacobson action, and certifying the class.
However, approximately 11 persons, including Benjamin Langford, have opted out
of the Jacobson action and this settlement and, therefore, are not barred by
the settlement from pursuing their own claims against the Company. Mr.
Langford's action is still pending against the Company, although it is no
longer a class action. The Company's motion to dismiss the Langford action was
denied and discovery is proceeding.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
10.1 Engagement Letter, dated as of
September 9, 1996, between Somanetics Corporation and
Gruntal & Co., Incorporated.
10.2 Consulting Order, dated as of October
1, 1996, among Somanetics Corporation and NeuroPhysics
Corporation, Hugh F. Stoddart and Hugh A. Stoddart,
Ph.D., as Consultants.
27.1 Financial Data Schedule
28
<PAGE> 29
PART II OTHER INFORMATION
(b) Reports on Form 8-K
The Company filed a Form 8-K, dated April 3, 1996, to announce under
Item 5 that it had completed the placement of 571,200 Units, at a
price $2.50 per Unit, for gross proceeds of $1,428,000 through an
offering complying with Regulation S under the Securities Act of
1933, as amended (the "Act"). Each Unit consists of two
newly-issued Common Shares, par value $0.01 per share, and one
warrant to purchase one Common Share.
The Warrants are immediately exercisable and transferable separately
from the Common Shares. Each Warrant entitles the holder to
purchase one Common Share at an initial exercise price of $1.75 per
share, subject to adjustment, at any time through April 1, 2001,
unless earlier redeemed. The Warrants are redeemable for $0.01 by
the Company at any time after July 2, 1996, if certain conditions
are met.
The Company also announced that it had granted the placement agent
warrants to purchase 114,240 Common Shares at $1.25 per share
exercisable during the four-year period beginning April 2, 1997.
29
<PAGE> 30
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Somanetics Corporation
----------------------------
(Registrant)
Date: October 11, 1996 By: /s/ Raymond W. Gunn
-----------------------
Raymond W. Gunn
Executive Vice President
and Chief Financial Officer
(Duly Authorized and
Principal Financial Officer)
30
